D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 Study Evaluating DM919, a Novel MICA/B Antibody for Treating Patients with Advanced Solid Tumors
Natick, Mass., April 19, 2024 — D2M Biotherapeutics, Inc. (D2M), a clinical stage biotech company focused on developing innovative therapies […]